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Conjugates of biotin with the decamer of glutamic acid (glul0) and the trimer of V,L-2-amino-5-
phosphonovaleric acid (I) have been synthesized, and it has been shown that they mediate the binding
of avidin to hydroxylapatite. In a similar way a conjugate of methotrexate with glulo mediates the
binding of dihydrofolate reductase to the mineral. The presentation ofligands on the hydroxylapatite
component of bone may find applications in clinical medicine.
Peptidescontainingseveralasparticand glutamic acid
residues,oligonucleotides,and other polyanions bind
strongly but reversiblyto hydroxylapatite;this is the
basisofhydroxylapatitechromatography (1,2). We have
recentlyfound that oligomers ofglutamic acid as short
as the hexamer bind quantitativelyto hydroxylapatite
and are not removed by washing with water or a 0.1 M
NaCl solution(3).This suggeststhat negativelycharged
polypeptidesmight be used as linkerstobind ligandsto
the mineral component ofbone with controllableaffinity
and retentiontime. In thispaper we show that conju-
gatesofbiotinand methotrexatewith negativelycharged
peptidesmay be used to mediate the binding of avidin
and dihydrofolatereductase,respectively,to hydroxyl-
apatite.
Glul0was synthesizedby the PeptideBiologyLabora-
tory at The Salk Institute.D,L-2-Amino-5-phosphono-
valericacid (I),methotrexate (MTX), chickenliverdihy-
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drofolatereductase(DHFR), and N-hydroxysuccinimide
(N-OH-succ) were obtained from Sigma; 1,l-carbonyl-
diimidazole(CDI) and dicyclohexylcarbodiimide(DCC)
were from Aldrich. Succinimidyl-6-(biotinamido)hex-
anoate (NHS-LC-Biotin H) was obtained from Pierce,
streptavidinfrom Boehringer, 12SI-labeledstreptavidin
from Amersham, and hydroxylapatite(HA) from Bio-Rad.
The biotin derivativeof glUl0 was synthesized by
reacting25 nmol ofthe oligomerwith 190 nmol ofNHS-
LC-Biotin IIin 20 pL of0.1 M NaHCO8 bufferatpH 8.4
for45 rain.The product was purifiedon a C18 column
using a 0.1% TFA/acetonitrilegradientand itsidentity
confirmed by LDMS (calculated for C66H97N13034S -_- Na +
1670.6; found 1670.7).
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The MTX derivative of glu_0 was synthesized via an
N-hydroxysuccinimide intermediate (4). A solution (40
pL) containing 0.05 M MTX, 0.05 M N-OH-succ, and 0.05
M DCC in DMF was allowed to stand at room temper-
ature for 1 h and then at 2-4 °C overnight. Ten
microliters of the resulting solution was added to 5-25
nmol ofglul0 in 30/_L of 0.02 M NaHCO3 at pH 8.2. The
reaction mixture was shaken in the dark for 4 h and then
diluted with 70/_L of water. Unreacted MTX and salts
were removed by shaking the reaction mixture with 10
mg of HA overnight, removing the supernatant, and
washing the HA with water. Glul0 and its MTX conju-
gate were eluted by shaking the HA with 2 × 50 pL of
0.02 M pyrophosphate for 30 rain. The conjugate was
purified by HPLC on a C18 column. Its identity was
confirmed by LDMS (calculatedfor CToH92N1803s -}-H +
1745.6;found 1745.0).
Oligomers ofD,L-2-amino-5-phosphonovalericacid(pvl)
were synthesizedfrom the monomer (I)using carbonyl-
diimidazole(CDI) as a condensing agent (5).A solution
of the monomer at pH 8 (0.05-0.1 M) was added to a
3-foldexcessofsolidCDI, and the resultingsolutionwas
allowedtostand for6 h (orovernight).Products ranging
from the dimer tothe pentamer were identifiedby paper
chromotography (n-PrOH/NHs/H20 7:1:2),and samples
ofthe oligomerswere eluted from the paper. HPLC of
the reactionmixture on an RPC-5 column gave a series
ofpeaks thatwere assigned tooligomersofknown length
by cochromatography with the material eluted from
paper.
To determine the shortestoligomerthat binds to HA,
2-3 pg ofthe dimer, trimer,tetramer,orpentamer was
separatelyshaken with 10 mg ofHA, and any oligomer
retainedby the HA was elutodwith K,PsO7 as described
above. HPLC analysisof the supernatant and IQP2Ov
eluateshowed that trimersand longeroligomers ofpvl
were found only in the eluate and thereforehad been
bound by the HA. Dimers were not bound to HA and
were found in the supernatant fraction.
To obtain the biotinderivativeof (pvl)3,6 pg of the
tripeptideisolatedfrom RPC-5 was firstadsorbed to 10
mg ofHA. The solidwas separatedby centrifugationand
washed with H20 toremove Trisand other components
ofthe HPLC buffer.(Pvl)3was then elutedwith pyro-
phosphate as describedabove. (Pvl)s(5-10/_g)in 20/_L
of buffer containing 0.2 M pyrophosphate and 0.2 M
NaI-ICO3 (pH 8.4)was added to0.1 mg ofsolidNHS-LC
Biotin II. The reactionmixture was then allowed to
stand forI h atroom temperature. The biotinylderiva-
tiveofthe tripeptidewas purifiedand isolatedusing an
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Table 1. Biotin-Mediated Binding of Streptavidin to
Hydroxylapatite
% [125I]streptavidin % [125I]streptavidin
in supernatant on hydroxylapatite
glulo 97 3
pvl3 97 3
biotin-glulo 25 75
biotin-pvla 32 68
RPC-5 column. Its identity was confirmed by ESMS
(calculated for C31H57NeO16P38 - H 893.2; found 893).
To recruit streptavidin to HA, 1 nmol of biotin-glUl0
or biotin-(pvl)3 was first shaken with 1 mg of HA in 20
pL of 0.01 M Tris-CIO4 for 6 h (or overnight) at room
temperature. The supernatant was removed by centrifu-
gation, and the HA was washed with 100/_L of water. A
solution of 0.1 nmol of 125I-labeled streptavidin (25 000-
50 000 cpm) in 100 pL of buffer containing 1 M KCI and
0.01 M phosphate at pH 6.5 was added to the HA and
shaken for 45 min. The supernatant was removed by
centrffugation and the HA washed several times with 200
pL of H20. The amounts of radioactivity found in the
supernatant, wash, and HA fractions were then mea-
sured (see Table 1). In control experiments, biotin-glUlo
was replaced by glUl0 and biotin-(pvl)3 was replaced by
(pvl)_. When a peptide bound to the HA was ligated to
biotin about 70% of the streptavidin was recruited to the
HA and 25-30% remained in the supernatant (Table 1).
In the control experiments no more than 5% of the
streptavidin was bound to the HA. Clearly the pread-
sorption of biotin conjugates of negatively charged polypep-
tides greatly enhances the adsorption of avidin to HA.
To recruit dihydrofolate reductase to HA, 1 nmol of
MTX-glUl0 was adsorbed to HA as described above for
biotin-glul0. DHFR (0.52 nmo]) in 200 pL of buffer
containing 0.1 M ammonium sulfate, 0.01 M potassium
phosphate, at pH 6.4, and 5% glycerol was added to the
HA and shaken for 45 rain. The HA was separated from
the supernatant, washed with 100/_L of water, and then
eluted twice with 20 pL of 0.02 M K4P207. In control
experiments the MTX-glUlo was replaced by glUl0. The
supernatant, the washes, and the pyrophosphate eluate
were analyzed on a 6% acrylamide SDS gel using Coo-
massie Blue to visualize DHFR. Figure 1 shows that in
the control experiments with glUl0 more than 75% of the
DHFR was found in the supernatant (Figure 1, lane 1)
and only a small amount in the pyrophosphate eluate
(Figure 1, lane 3). In experiments involving MTX-glul0
more than 75% of the DHFR was found in the pyrophos-
phate eluate (Figure 1, lane 6) and very little in the
supernatant (Figure 1, lane 4). Preadsorption of
MTX-glulo, therefore, greatly increases the amount of
DHFR that binds to HA.
The above results show that conjugates of various
ligands with anionic polypeptides adsorbed noncovalently
on hydroxylapatite could be used as supports for affinity
chromatography. More importantly, HA presents special
opportunities in a related context, because it is the main
mineral component of bone. The surface of bone is freely
accessible to molecules in the extracellular fluid even if
they are as large as proteins (6). The bisphosphonates,
small molecules carrying four negative charges, have
been used extensively to attach technetium to hydroxyl-
apatite for bone scintigraphy (7). One example of the
recruitment of an anticancer drug, methotrexate, to bone
using a bisphosphonate has been reported (8). We believe
that anionic polypeptides may prove particularly conve-
nient as carriers of ligands to bone and may sometimes
have advantages over the bisphosphonates.
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Figure 1. Coomassie Blue stained SDS gel showing DHFR in
the supernatant (lanes 1 and 4), the wash (lanes 2 and 5), or
the pyrophosphate eluate (lanes 3 and 6) after shaking a
solution of the enzyme with glulo-bound hydroxylapatite (HA)
(lanes 1-3) or with MTX-glulo-bound HA (lanes 4-6). One
nanomo]e of glul0 or MTX-glul0 was shaken with 1 mg of HA
for 6 h. Excess peptide was removed by washing. The glulo- or
MTX-glUlo-bound HA was then shaken with 0.52 nmol of DHFR
for 45 rain. The supernatant was removed by centrifugation and
the HA washed with 100 pL of water. The glulo and MTX-glum
together with any bound DHFR were eluted from the HA by
shaking with 2 x 50/_L of pyrophosphate solution for 30 rain.
The mechanism of action of bisphosphonates on bone
resorption is not fully understood, but it seems clear that
it is not entirely a matter of adsorption to hydroxyl-
apatite. The properties of osteoblasts are profoundly
affected by submicromolar concentrations ofbisphospho-
nates, suggesting that they attach to receptors, possibly
pyrophosphate receptors, on the cell surface (9). The
structures of polypeptides are completely unrelated to
that of inorganic pyrophosphate, so by using them as
carriers it should be possible to dissociate the direct
effects of adsorption to HA from the indirect effects due
to interaction with extracellular receptors on osteoblasts
(or osteoclasts).
Polypeptides are uniquely convenient as carriers,
because effective automated methods are already avail-
able for their synthesis, and the use of combinatorial
peptide libraries is well-established. The strength of
adsorption of the carriers could easily be controlled via
their length, while more or less degradable carriers could
be obtained by varying the ratio of D- to L-residues. In
the special case of a peptide ligand, the ligand and the
anionic carrier could be assembled in a single solid-phase
peptide synthesis. Presentation of ligands on HA that
interact directly with receptors on osteoblasts or osteo-
clasts, or which recruit proteins to bone, may find
applications in medicine.
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